mirtazapine has been researched along with Aggressive Systemic Mastocytosis in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Aggressive Systemic Mastocytosis: A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Šakić, B | 1 |
Greš, A | 1 |
Gajić, Z | 1 |
1 other study available for mirtazapine and Aggressive Systemic Mastocytosis
Article | Year |
---|---|
Mirtazapine-Induced Hyponatremia in a Patient with Systemic Mastocytosis and Generalized Anxiety Disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Humans; Hyponatremia; Mastocytosis, Systemic; M | 2023 |